← ANALYST RATINGS · TIPRANKS
Elanco Animal Health (ELAN): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy1 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $31.60, the highest $34.00, the lowest $26.00. The average is +34.2% from the last price of $23.55.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $24.50 → $26.00+6.1% | Hold | +10.4% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $24.00 → $25.00+4.2% | Hold | +6.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $23.50 → $25.00+6.4% | Hold | +6.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $22.50 → $24.00+6.7% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $25.00 → $26.00+4.0% | Buy | +10.4% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $24.50 → $26.00+6.1% | Hold | +10.4% | Downgrade | 17.10.26on TipRanks 00:06 | — | |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $33.00 | Buy | +40.1% | Reiterated | 16.10.26on TipRanks 07:55 | +1.1% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $34.00 | Buy | +44.4% | Reiterated | 01.10.26on TipRanks 14:00 | −2.9%next day +1.0% · 5 days +2.2% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | — | Buy | — | Reiterated | 18.09.26on TipRanks 08:40 | −1.5%next day −1.5% · 5 days −1.8% | ↗ |
| Steve Scala★★★★★★★★★★#1275 · hits 63% · avg +10.5% | TD Cowen | $32.00 | Buy | +35.9% | Assigned | 25.08.26on TipRanks Aug 24 18:30 | +2.4%next day −0.1% · 5 days −4.2% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $30.00 | Buy | +27.4% | Reiterated | 21.08.26on TipRanks Aug 24 04:45 | +1.3%next day +2.2% · 5 days +0.1% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $32.00 → $34.00+6.2% | Buy | +44.4% | Reiterated | 12.08.26on TipRanks Aug 13 06:55 | −2.9%next day +1.0% · 5 days +11.2% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Buy | — | Reiterated | 12.08.26on TipRanks 11:55 | −2.9%next day +1.0% · 5 days +11.2% | ↗ |
| Erin Wright★★★★★★★★★★#354 · hits 64% · avg +15.1% | Morgan Stanley | $26.00 | Hold | +10.4% | Assigned | 10.08.26on TipRanks 08:20 | +0.8%next day +2.3% · 5 days +6.0% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $30.00 | Buy | +27.4% | Reiterated | 10.08.26on TipRanks 07:25 | +0.8%next day +2.3% · 5 days +6.0% | ↗ |
| Andrea Alfonso★★★★★★★★★★#2181 · hits 100% · avg +43.2% | UBS | $31.00 → $33.00+6.5% | Buy | +40.1% | Reiterated | 06.08.26on TipRanks 08:01 | −7.5%next day −9.2% · 5 days −8.2% | ↗ |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $31.00 → $34.00+9.7% | Buy | +44.4% | Reiterated | 06.08.26on TipRanks 06:56 | −7.5%next day −9.2% · 5 days −8.2% | ↗ |
| Scott Schoenhaus★★★★★★★★★★#12104 · hits 35% · avg −9.7% | KeyBanc | $30.00 | Buy | +27.4% | Reiterated | 06.08.26on TipRanks 04:16 | −7.5%next day −9.2% · 5 days −8.2% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | — | Buy | — | Reiterated | 23.06.26on TipRanks Jun 24 09:25 | −1.6%next day +3.4% · 5 days +4.4% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 11.05.26on TipRanks 09:15 | −8.4%next day −1.2% · 5 days −8.2% | ↗ |
| Unknown Analyst | Jefferies | $30.00 | Buy | +27.4% | Reiterated | 25.02.26on TipRanks 15:14 | +0.9%next day −1.9% · 5 days −7.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Elanco Animal Health
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $31.44 at a price of $22.39 (+40.4%); now: $31.60 at $23.55 (+34.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 2 |
| Buy | 13 | 16 | 12 | 17 | 12 | 13 |
| Hold | 1 | 2 | 4 | 4 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 06.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.21 (from $0.19 to $0.24). Last quarter: $0.34.
Sales
Next quarter’s sales estimate — $1.2B (from $1.2B to $1.2B). Last quarter: $1.4B.
Best top-analyst consensus in the sector · Healthcare
About Elanco Animal Health
- CEO: Jeffrey N. Simmons
- Employees: 9,650
- 450 Elanco Circle, Indianapolis, IN, 46221, US
- www.elanco.com
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Data from the stock’s TipRanks forecast page, read 11 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗